TP53 mutation is enriched in colorectal cancer liver metastasis in the context of polyclonal seeding.


Journal

Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 09 02 2022
revised: 20 05 2022
accepted: 25 05 2022
pubmed: 10 6 2022
medline: 5 8 2022
entrez: 9 6 2022
Statut: ppublish

Résumé

Cancer metastasis accounts for the majority of cancer motility burden. For colorectal cancer (CRC), the liver is the most common site of distant metastasis. It is still little known that cancer genomic mutations, which are a cell-intrinsic and heritable property, are enriched in CRC liver metastasis. Here, we try to answer the question in the context of polyclonal seeding. In this study, we sequenced 18 pairs of colorectal cancer primary tumors and their matched liver metastasis samples. Together with public available sequencing data, we compared the mutations in 113 primary and metastasis pairs. The TP53 mutation variant allele frequency (VAF) was significantly increased in metastasis compared to the paired primary tumor, although most of the frequently observed mutations in liver metastasis foci were concordant with their matched CRC primary tumors. The results support late metastasis and polyclonal seeding. Consequently, we quantitatively compared the intratumor heterogeneity (ITH) between primary and metastasis tumors, and with the help of in silico metastasis simulation, we inferred that more than 10 cells take part in the CRC liver metastasis.

Identifiants

pubmed: 35679752
pii: S0344-0338(22)00202-3
doi: 10.1016/j.prp.2022.153958
pii:
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

153958

Informations de copyright

Copyright © 2022 Elsevier GmbH. All rights reserved.

Auteurs

Wenjie Sun (W)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China; Institut Curie, PSL Research University, Inserm, CNRS, Paris 75005, France.

Qingrong Sun (Q)

Department of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing 21198, China.

Anjing Zhong (A)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China.

Anne-Marie Lyne (AM)

Institut Curie, PSL Research University, Inserm, CNRS, Paris 75005, France.

Dongdong Huang (D)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China.

Fengyan Han (F)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China.

Maode Lai (M)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China; Department of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing 21198, China. Electronic address: lmp@zju.edu.cn.

Honghe Zhang (H)

Department of Pathology, Key Laboratory of Disease Proteomics of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou 310058, China. Electronic address: honghezhang@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH